Bioactive Glass Market
The future of the global bioactive glass market looks promising with opportunities in the orthopedic, dentistry, cosmetic, and drug delivery markets. The global bioactive glass market is expected to reach an estimated $487.4 million by 2035 from $257.1 million in 2027 with a CAGR of 8.7% from 2027 to 2035. The major drivers for this market are the increasing use in bone regeneration, the rising demand for dental applications, and the growing focus on biocompatible materials.
- Lucintel forecasts that, within the type category, 45S5 is expected to witness higher growth over the forecast period due to superior bioactivity preferred in 45S5 bioactive glass compositions.
- Within the application category, orthopedics is expected to witness the highest growth over the forecast period due to expanding orthopedics requiring bioactive glass implant materials.
- In terms of regions, North America is expected to witness the highest growth over the forecast period due to established medical device sector and continuous regenerative medicine demand.
Emerging Trends in Bioactive Glass Market
Growing use of bioactive glass in engineered biomaterials is expected to propel the market beyond dental and wound care. Development will predominantly be in the field of orthopedics and other tissue engineering and regeneration. Between 2025-2027, market potential will be measured by the pace of clinical evidence, reimbursement and the development of large-scale manufacturing. Lucintel believes that competitors will compete based on process and composition control.
- Sustainability: Lower-temperature melting points and increased use of recycled cullet are expected to be adopted by manufacturers as components allow, 45S5 formulations can retain ion-release activity with additional material controls. This will impact purchasing as hospitals qualify vendors based on carbon and waste footprint.
- Digital Manufacturing: By 2025, process analytics will shift production toward particle size and thermal profiles, enabling better control of variability in lots and potentially reducing scale-up time to support regulatory submissions to 2030.
- Clinical Grade Specialization: By 2026, the market will differentiate commodity powders from those tailored for 45S5, 58S, and S53P4 to meet the needs of specific bone defects and/or antimicrobial applications, and value will continue to be tied to ion release. Premium products should capture higher margins, especially if evidence shows they reduce risk to the surgeon.
- Functional Products: The market will see the emergence of bioglass-based products in injectable pastes and composites, and controlled release systems. While particle size may impact some aspects of product performance, for example handling, manufacturing and marketing sterile products will remain a challenge. Demand for these products will increase beyond traditional graft substitutes in the next five years.
- Regional Supply Chain Diversification: By 2027, buyers will be qualifying two different supply sources for specialty powders and milling because dependence on a single plant creates supply risk for the medical device. Additional production in North America and Europe will complement existing facilities in Asia. This will drive changes to supply contracts and qualification.
We believe the bioactive glass market is likely to reward companies for innovative material design in conjunction with repeatable clinical outcomes. We expect that the adoption of regenerative solutions by surgeons will increase demand, although the pace of qualification will remain slow and evidence-based. Companies that control particle size and/or ion release and sterilization and regulatory processes will set the margins. Long-term, capacity and relationships with device manufacturers and hospitals will be important.
Recent Developments in the Bioactive Glass Market
Bioactive glass markets picked up in 2025 and beyond will remain largely investment-oriented to 2027. Companies have primarily shifted from lab-scale formulations to controlled granules, putties and coatings. Dental applications have sustained a good market pull. Through 2027, Lucintel expects capacity, regulatory, and hospital adoptions will play a major role in domination in bone repair applications.
- Production Scale-up: In March 2025, Bonalive reported S53P4 was used in more than 50,000 surgeries. This established clinical base instilled confidence among orthopedic distributors and hospitals to increase their purchases.
- Regulatory Broadening: During 2025, bioactive glass suppliers expanded the use of bioactive glass grafts and putties to a broader market, beyond the specialty market, by pursuing more 510(k) submissions. The more clearances received, the larger the addressable market becomes, and fewer barriers to adoption exist over the next three to five years.
- Dental Product Development: In June 2025, commercial formulations in the dentin sensitivity and remineralization markets continued to target particle sizes less than 100 micrometres. Dental products have a shorter time to market compared to orthopedic products, and so can provide revenue sooner to a manufacturer.
- Strategic Collaboration: In September 2025, university-industry partnerships reported clinical studies with more than 100 patients for bioactive glass-based bone-repair products. Clinical studies provide regulatory dossiers and support a company's product claims.
- Manufacturing Technology: In February 2026, producers indicated tighter control over particle-size distribution, and automated melting, with batch-to-batch variation targets near 5%. Release of ions in a consistent manner lowers rejection and makes the material easier to incorporate into company-specific products.
Repeatable manufacturing and reimbursement will be more important than new discoveries. Suppliers that document ion release, sterility, and shelf-life win hospital business. High volume, but low value, dental business, can be captured in the short term. The value is in orthopedic reconstruction. Partnerships between material, device, and distribution companies can help speed up and validate products in the market over the next few years.
Strategic Growth Opportunities in the Bioactive Glass Market
From 2024 - 2026, the bioactive glass market is transitioning away from bone repair markets and more towards clinical and industrial markets. Factors such as limited hospital capacity, aging populations, the economics of infection control, the cost effectiveness of additive manufacturing and further refinement in bioactive glass chemistry and products are fueling buyer's expectations. In the next 3 - 5 years, wound care product providers will prefer mineral based products that lower infection costs and reduce the number of clinic visits.
- Dental Remineralization: BioMin in February 2025 set its minimum level of bioactive glass at 5%. Sustained preventive care will likely enable a shift from infrequent professional cleanings to daily home care with bioactive glass.
- Additive-manufactured Scaffolds: Porous bioactive glass can better address complex defects as compared to standard bone grafts. In September 2025, a study described scaffolds with 70% interconnected porosity. Over three to five years, the demand for patient-specific implants will drive this segment away from the laboratory.
- Geographic Expansion: Local knowledge of laws and reimbursement provides entry outside North America and Western Europe. In March 2025, BonAlive announced S53P4 commercial presence in 30+ countries. Distributor-led expansion and increasing trauma in the population will develop surgical markets.
- Premium Antimicrobial Coatings: Implant coatings with controlled ion release and strong adhesion can charge higher prices. In July 2025, a lab test showed a 99.9% reduction in a target bacterial strain. Over three to five years, the focus on infection control will drive the use of bioactive glass coatings.
In the next five years, the market will move beyond simply selling bioactive glass. Clinician training, regulation and reimbursement will also be essential. Orthopedic coatings and scaffolds will likely take longer to gain traction compared to dentistry and wound care. For all products, control of the composition will allow suppliers to defend margins due to increasing demands.
Bioactive Glass Market Drivers and Challenges
The growth of the bioactive glass market is reliant on numerous factors such as clinical demand, the innovation of materials, the availability of capital in the healthcare sector, sustainable development, and changing regulations. The market is expected to benefit from the advances being made in the area of tissue engineering. The Lucintel report acknowledges the role of production costs and validation in product commercialization. However, the market is challenging due to high costs of manufacturing, lack of long-term clinical data, complex and fragmented regulations, and inconsistent quality of raw materials.
The factors responsible for driving this market include:
- Customer Demand: There is increasing customer demand for bioactive glass for support and facilitation of mineralization and tissue repair due to rising cases of dental caries and periodontal diseases, as well as for repair and reconstruction of bone defects and in dental implant procedures. In March 2025, the World Health Organization reported that oral diseases impact nearly 3.5 billion individuals worldwide and create a significant, unmet demand for restorative and preventive products. Rising awareness, accessibility, and affordability of orthopedic care should stimulate the use of bioactive glass over the next 3 to 5 years in a wide range of bio-restorative and bio-regenerative products.
- Development of New Technologies: Improvements in sol-gel processing, nanotechnology, ion-substitution, additive manufacturing (AM) and design of composites, further improve the potential of bioactive glass. Additionally, research activities in the fields of therapeutic ions, such as strontium, zinc, copper and silver, advanced formulations of bioactive glasses, are ongoing. It is expected that during the next 3-5 years, new products based on bioactive glasses will become available and stimulate the use of bioactive glasses for novel applications, and extend the market beyond traditional dental and craniofacial as well as orthopedic applications.
- Regulatory Support: Simplified medical-device pathways and recognition of advanced biomaterials by regulatory agencies should reduce uncertainty and attract investment. Currently, in the European Union (EU), the Medical Device Regulation allows manufacturers to extend the deadlines of "Legacy" Medical Devices until December 2027. This extension allows manufacturers to complete their compliance activities. It is expected that during the next 3-5 years, more definitive test methods will be available for assessment of biocompatibility, and clinical performance. These will facilitate product approval. More definitive test methods for ion release and device degradation will help complete the risk management of the medical devices. Regulatory support will be of most benefit to a company when the other aspects of the product (documentation, controls, and clinical evidence) are also completed.
- Sustainability: Bioactive glasses have the potential to facilitate minimally invasive procedures, decrease reliance on autografts, and enable the development of more durable restorative solutions. Although the application of industrial and mineral by-products may be an option for the future, purity and medical-grade consistency are essential. The European Union's (EU) Packaging and Packaging Waste Regulation (2025/2024) came into force in February 2025, placing additional obligations on manufacturers to achieve more resource-efficient and greater environmentally-friendly production. It is anticipated that over the next 3-5 years, device and hospital producers will start evaluating the lifecycle performance, energy use and consumption, packaging, and sourcing when selecting biomaterial suppliers.
- Manufacturing Efficiency: Over the past several years, advancements in melting and sol-gel synthesis, as well as automation in quality control, powder processing, and spray drying have made it easier to achieve more consistent and consistent particle size and composition. This has facilitated scale-up, leading to reductions in unit costs, and improved the reproducibility needed to manufacture regulated medical devices. In January 2025, digital manufacturing initiatives across the healthcare sector focused more and more on real-time control and monitoring of at least 3 critical process parameters: temperature, composition and particle size/shape. It is expected that process automation and the development of standardized production will, within the next three to five years, improve the yields and reduce cycle times for the synthesis of bioactive glass, making it more competitive in the high-volume dental and orthopedic device markets.
The challenges facing this market include:
- High Production Costs: The costly nature of producing bioactive glass is due to high process temperatures requiring specialized high temperature furnaces, high purity and controlled raw material atmospheres. Additional costs are related to small batch production, milling, and sterilization and testing of the finished devices. In January 2025, elevated industrial energy prices in most regions, compared to 2020 levels, kept thermal processing economically sensitive, even with moderate price decreases from earlier peak levels. In the next three to five years, the overall economy, energy price volatility, and limited economies of scale, may adversely affect industry players.
- Material Consistency and Adoption Barriers: Variations in purity, size, surface area, composition and dissolution behavior of raw materials used to manufacture bioactive glass products may contribute to inconsistent clinical outcomes. Hospitals and clinicians may be comfortable using grafts, ceramics, polymers and autologous procedures, for which reimbursement is uncertain. In June 2025, quality teams used at least 3 major control stages, i.e. raw material inspection, in-process testing and final-product testing, to limit batch-to-batch variation. It is anticipated that in the next 3-5 years, manufacturers of bioactive glass products will have to demonstrate repeatable and long-term safety, substantial clinical benefits, and provide a convincing economic case in order to achieve widespread adoption.
- Regulatory and Clinical Complexity: Bioactive glass products may be regulated differently based on their composition, intended use, claims, delivery format, and whether they are classified as devices, combination products, or medicinal active products. In December 2025, manufacturers operating under the European Medical Device Regulation still had to meet several other requirements, including biological evaluation, risk management and post market surveillance. It is anticipated that in the next 3-5 years, lengthy clinical validation in conjunction with differences in regional regulations will result in a significant delay in product launches. Companies that can create a unified testing strategy, and partner effectively with clinicians, will be best prepared to mitigate approval and launch timeframes.
The bioactive glass market is expected to rise due to growth in dental and orthopedic care as well as tissue engineering and regenerative medicine. Improvements in technology and manufacturing automation is expected to increase product capabilities and affordability, while sustainability and regulatory progress would drive additional investments. However, high production costs, variable material quality, and uneven clinical adoption would continue to limit the market. Those companies that integrate validated formulations, automate manufacturing, and align supply chains with clinical data would have a competitive advantage. Ultimately, transforming scientific discoveries to produce affordable, consistent and regulatable solutions would enable market growth and improve access to healthcare for the general population.
List of Bioactive Glass Market Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies bioactive glass market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the bioactive glass market companies profiled in this report include-
- Schott
- Mo-Sci Corporation
- Biomet 3i
- BonAlive Biomaterials
- NovaBone Products
- Synergy Biomedical
- Stryker Corporation
- Zimmer Biomet Holdings
- Johnson & Johnson
- Royal DSM
Bioactive Glass Market by Segment
The study includes a forecast for the global bioactive glass market by type, application, end use, and region.
Bioactive Glass Market by Type [Value ($M) from 2019 to 2035]:
Bioactive Glass Market by Application [Value ($M) from 2019 to 2035]:
- Orthopedics
- Dentistry
- Cosmetics
- Drug Delivery
- Others
Bioactive Glass Market by End Use [Value ($M) from 2019 to 2035]:
- Hospitals
- Clinics
- Research Institutes
- Others
Bioactive Glass Market by Region [Value ($M) from 2019 to 2035]:
- North America
- Europe
- Asia Pacific
- The Rest of the World
Country Wise Outlook for the Bioactive Glass Market
Bioactive glass is advancing beyond its traditional applications in dental and wound care to other orthopedic, coating and regenerative medicine applications. The 2025-2027 period sees commercialization efforts related to public funding, advanced materials policies and localization of medical device manufacturing. According to Lucintel, application broadening is the main driver for the bioactive glass market.
- United States: The FY2025 Consolidated Appropriations Act provided approximately $47.5 billion for the National Institutes of Health (March 2025). This will support translational bio-materials and medical devices research, and probably sustain University based industry validation programs and local research and development in the bioactive glass and related wound and dental care products.
- China: Advanced-Materials Policy: China's 2025 Government Work Report set a target to boost research and development spending to 2.8% of GDP by March 2025. This represents a growing commitment to state-backed R&D. This matters because it will allow China to accelerate the production of bioactive glass for use in orthopedic and dental devices.
- Germany: Industrial Investment Framework: The German Bundestag passed a law in March 2025 that allows the creation of a €500 billion special fund to invest in infrastructure and other projects. Alongside other changes to German fiscal rules, this measure will likely strengthen Germany's manufacturing base and related research infrastructure, as well as its capacity to process materials used in medical glass production.
- India: Private R&D Financing: India's Union Budget 2025-26 set aside ₹1 lakh crore for private sector R&D and innovation (February 2025). This is likely to improve funding for indigenous bio-materials research, clinical translation, and the manufacture of medical devices at scale in India over the next 3-5 years.
- Japan: Public Investment Framework: Japan's FY2025 budget (March 2025) allocated significant resources to R&D and innovation in advanced manufacturing. This will accelerate domestically-driven research, precision-based manufacturing and partnerships, and integration of bioactive glass for dental and orthopedic applications.
Features of the Global Bioactive Glass Market
- Market Size Estimates: bioactive glass market size estimation in terms of value ($B).
- Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
- Segmentation Analysis: bioactive glass market size by type, application, end use, and region in terms of value ($B).
- Regional Analysis: bioactive glass market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
- Growth Opportunities: Analysis of growth opportunities in different types, applications, end uses, and regions for the bioactive glass market.
- Strategic Analysis: This includes M&A, new product development, and competitive landscape of the bioactive glass market.
Analysis of competitive intensity of the industry based on Porter's Five Forces model.
If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.
This report answers following 11 key questions:
- Q.1. What are some of the most promising, high-growth opportunities for the bioactive glass market by type (45S5, S53P4, and others), application (orthopedics, dentistry, cosmetics, drug delivery, and others), end use (hospitals, clinics, research institutes, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
- Q.2. Which segments will grow at a faster pace and why?
- Q.3. Which region will grow at a faster pace and why?
- Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
- Q.5. What are the business risks and competitive threats in this market?
- Q.6. What are the emerging trends in this market and the reasons behind them?
- Q.7. What are some of the changing demands of customers in the market?
- Q.8. What are the new developments in the market? Which companies are leading these developments?
- Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
- Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
- Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?